The IL11 Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human pancreatic ductal adenocarcinoma cell line PaTu 8988t. These cells carry a targeted disruption of the IL11 gene, resulting in a loss-of-function model for studying IL-11 signaling in pancreatic cancer biology. The polyclonal nature of this knockout product ensures representation of a broad spectrum of genetic backgrounds, making it suitable for population-based functional studies without the bias of clonal selection.
The PaTu 8988t cell line was established from a liver metastasis of pancreatic ductal adenocarcinoma and exhibits an adherent epithelial morphology. It is widely employed as a model system for investigating the molecular mechanisms underlying PDAC progression, metastasis, and the tumor microenvironment. The liver-metastasis origin makes it particularly relevant for studies of hepatic colonization and metastasis-associated signaling.
IL-11 functions as a pleiotropic cytokine that binds to its specific receptor IL-11R?? and the co-receptor gp130 (IL6ST), triggering activation of receptor-associated JAK1. This leads to phosphorylation and nuclear translocation of STAT3, which drives transcription of downstream targets including Bcl-2, Cyclin D1, VEGF, MMP9, and Snail. In parallel, IL-11 signaling engages the MAPK/ERK and PI3K-AKT pathways through adaptor proteins such as SHP2, promoting cell proliferation, survival, and migration. Upstream regulators such as TGF-??, IL-1, and TNF-??, as well as hypoxia and mechanical stress, converge to induce IL11 expression in the tumor microenvironment.
In the context of pancreatic ductal adenocarcinoma, IL-11 is frequently overexpressed and contributes to tumor cell proliferation, metastatic spread, and the development of cancer-associated fibrosis. The PaTu 8988t cell line, with its inherent metastatic phenotype, combined with IL11 disruption, offers a powerful system to dissect the contribution of IL-11 to liver metastasis and stromal interactions. This knockout model allows researchers to examine how loss of IL-11 signaling impacts tumor cell behavior and the surrounding microenvironment.
These polyclonal knockout cells are suitable for a wide range of experimental applications, including phospho-STAT3 analysis, proliferation and migration assays, invasion studies, and co-immunoprecipitation experiments to explore IL-11 receptor interactions. They can be employed in RNA-seq and RT-qPCR profiling to identify IL-11-dependent transcriptional programs, as well as drug sensitivity screens to assess the role of IL-11 signaling in therapeutic resistance. Additionally, this model is valuable for functional genomics studies aimed at uncovering novel regulators of the IL-11 pathway in pancreatic cancer. For further details, please contact Ascent Research.
